Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
25 hedge funds and large institutions have $31.9M invested in Bellerophon Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less capital invested
Capital invested by funds: $37.4M → $31.9M (-$5.48M)
17% less funds holding
Funds holding: 30 → 25 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$58.1K |
| 2 |
Renaissance Technologies
New York
|
+$40.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.2K |
| 4 |
VF
Virtu Financial
New York
|
+$13.4K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$285K |
| 3 |
TI
Telemetry Investments
New York
|
-$73K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$49K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$30K |
BLPH Hedge Fund Activity: Q4 2018 in Review
25 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2018, worth a combined $31.9M — down 15% from $37.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BLPH and 2 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $58.1K. The largest seller was Boxer Capital, exiting entirely with an estimated $1.6M sold.
- 25 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2018, down from 30 in Q3 2018.
- Funds reported $31.9M of Bellerophon Therapeutics, Inc. stock for Q4 2018, down 15% quarter-over-quarter.
- 2 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2018 and 7 closed out, a net change of -5 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q4 2018 was Bridgeway Capital Management, an estimated $58.1K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q4 2018 was Boxer Capital, an estimated $1.6M sold.
Based on aggregated 13F filings for Q4 2018.